A61K 31/192
Having aromatic groups
Official title: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
A61K31/192 (Having aromatic groups) appears on 3,025 US grants and 5,510 published applications in this corpus.
Search patents in A61K- Granted patents
- 3,025
- Published applications
- 5,510
- Assignees
- 2,091
- Inventors
- 8,623
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 2 | 0 |
| 1994 | 2 | 0 |
| 1995 | 10 | 0 |
| 1996 | 34 | 0 |
| 1997 | 71 | 0 |
| 1998 | 52 | 0 |
| 1999 | 72 | 0 |
| 2000 | 59 | 0 |
| 2001 | 59 | 24 |
| 2002 | 52 | 72 |
| 2003 | 50 | 150 |
| 2004 | 51 | 146 |
| 2005 | 25 | 106 |
| 2006 | 68 | 152 |
| 2007 | 38 | 148 |
| 2008 | 40 | 140 |
| 2009 | 35 | 142 |
| 2010 | 38 | 187 |
| 2011 | 54 | 176 |
| 2012 | 72 | 172 |
| 2013 | 113 | 219 |
| 2014 | 145 | 320 |
| 2015 | 164 | 299 |
| 2016 | 160 | 338 |
| 2017 | 185 | 300 |
| 2018 | 196 | 307 |
| 2019 | 178 | 286 |
| 2020 | 176 | 302 |
| 2021 | 172 | 259 |
| 2022 | 141 | 306 |
| 2023 | 130 | 287 |
| 2024 | 132 | 276 |
| 2025 | 151 | 223 |
| 2026 | 94 | 173 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Powder mixing device, and uses thereof6 Oct 2026US 12,751,925 B2University of Connecticut
- Prevention of viral transmission through feed6 Oct 2026US 12,751,931 B2Dsm IP Assets B.V.
- Small molecule inhibitors of viral replication6 Oct 2026US 12,751,963 B2The Trustees of Princeton University
- API stability in softgels29 Sep 2026US 12,746,206 B2R.P. Scherer Technologies, LLC
- Compositions comprising HDAC inhibitors and retinoids22 Sep 2026US 12,740,953 B2The Regents of the University of California
- Silica-based nanoparticles for sustained release of hydrophobic drug, preparation method therefor, and transdermal drug delivery system comprising same8 Oct 2026US 2026/0306418 A1Mpios Inc.
- Combination treatment for netherton syndrome8 Oct 2026US 2026/0306448 A1Quoin Pharmaceuticals, Inc.
- Tomm6-interacting extracts and compounds for use in the treatment and prophylaxis of nervous system diseases, atherosclerosis, hepatitis b infection and human papilloma virus (hpv) infection8 Oct 2026US 2026/0306473 A1
- Sensor for analyte monitoring with drug-eluting capabilities1 Oct 2026US 2026/0294292 A1Senseonics, Incorporated
- Pharmaceutical composition comprising ibuprofen1 Oct 2026US 2026/0294855 A1
Most cited
By later US patents
- Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use354US 5,091,171 A1992
- Pharmaceutical formulation containing gelling agent198US 8,337,888 B2Purdue Pharma L. P. · 2012
- Recombinant A2-specific TNFα specific antibodies174US 7,070,775 B2Centocor, Inc. · 2006
- Multilayer dosage forms containing NSAIDs and triptans158US 7,332,183 B2Pozen Inc. · 2008
- Agents acting against hyperreactive and hypoactive, deficient skin conditions and manifest dermatitides149US 5,952,373 ABeiersdorf AG · 1999